Insights with Goldman Sachs Part 6: Generating investor interest
Good news! We’re currently seeing one of the largest pools of capital invested in biopharma. Generalist capital is coming back to the market. There’s a shift toward later-stage assets, but investors will be looking for proof points across different stages of development. Get more insights from Lyla Bibi, Managing Director, Head of Americas Healthcare Equity Capital Markets at Goldman Sachs.
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action.